Methotrexate |
T lymphocytes |
Reduction of synovial layer
thickness |
[15, 17] |
Macrophages |
Reduction of CD3, CD4, CD8,
CD68 sublining infiltration |
? others |
Reduction of polyclonal,
inflammation-related CD4+ T cells, smaller effect on oligoclonal CD8 T
cells |
|
Infliximab |
TNF |
Reduction of synovial layer
thickness |
[22-24, 26,28] |
Reduction of vascularity and
endothelial cell activation |
|
Adalimumab |
TNF |
Reduction of the synovial layer
thickness |
[27] |
Reduction of CD3 infiltration |
Reduction of MMP-13 expression |
|
Etanercept |
TNF, lymphotoxin |
Reduction of the synovial layer
thickness |
[11] |
Reduction of CD68+ and CD163+
macrophages |
Reduction of MMP-3 and MMP-9 |